B. Metzler seel. Sohn & Co. AG Has $2.33 Million Holdings in Medpace Holdings, Inc. $MEDP

Key Points

• B. Metzler seel. Sohn & Co. AG reduced its holdings in Medpace by 13.7%, now owning 7,631 shares valued at approximately $2.3 million.
• Medpace's latest quarterly earnings showed $3.10 EPS, exceeding analyst expectations, with a revenue of $603.31 million, up 14.2% year-over-year.
• Analysts have set new price targets for Medpace, with Barclays raising it to $450 and Robert W. Baird to $490, while the stock has a consensus rating of "Reduce."

B. Metzler seel. Sohn & Co. AG decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 13.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,631 shares of the company's stock after selling 1,211 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Medpace were worth $2,325,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Redwood Investment Management LLC bought a new stake in Medpace during the 1st quarter valued at approximately $1,341,000. FORA Capital LLC bought a new stake in Medpace during the 1st quarter valued at approximately $1,475,000. Caisse DE Depot ET Placement DU Quebec boosted its stake in Medpace by 32.1% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 230,524 shares of the company's stock valued at $70,238,000 after purchasing an additional 55,955 shares during the period. Synovus Financial Corp lifted its position in shares of Medpace by 76.5% in the 1st quarter. Synovus Financial Corp now owns 2,649 shares of the company's stock worth $807,000 after acquiring an additional 1,148 shares during the period. Finally, AlphaQuest LLC lifted its position in shares of Medpace by 292.8% in the 1st quarter. AlphaQuest LLC now owns 1,308 shares of the company's stock worth $399,000 after acquiring an additional 975 shares during the period. Institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on MEDP. Truist Financial raised their price objective on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research report on Wednesday, July 23rd. Mizuho raised their price target on Medpace from $328.00 to $510.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Robert W. Baird raised their price target on Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. TD Cowen reissued a "sell" rating and issued a $366.00 target price (up from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research note on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Medpace has an average rating of "Reduce" and a consensus price target of $406.60.

Medpace Trading Down 0.6%

Shares of NASDAQ:MEDP traded down $2.86 during midday trading on Tuesday, hitting $472.65. The company had a trading volume of 175,077 shares, compared to its average volume of 446,946. The firm has a fifty day simple moving average of $399.08 and a 200 day simple moving average of $340.31. The stock has a market cap of $13.28 billion, a price-to-earnings ratio of 35.08, a PEG ratio of 2.99 and a beta of 1.44. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $501.30.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million for the quarter, compared to analyst estimates of $537.70 million. During the same period in the previous year, the company posted $2.75 earnings per share. The company's quarterly revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In related news, VP Susan E. Burwig sold 7,500 shares of the company's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $450.14, for a total transaction of $3,376,050.00. Following the sale, the vice president owned 57,500 shares in the company, valued at approximately $25,883,050. This represents a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO August J. Troendle sold 620 shares of the company's stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $475.00, for a total value of $294,500.00. Following the sale, the chief executive officer owned 961,995 shares in the company, valued at $456,947,625. The trade was a 0.06% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 115,070 shares of company stock valued at $52,085,751 in the last ninety days. Insiders own 20.30% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.